Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapy

25 Feb 2025

Abstract excerpt

BACKGROUND: Glioblastoma (GBM) carries a poor prognosis, and new therapeutic strategies are necessary to improve outcomes for patients with this disease. Alkylating chemotherapies including temozolomide (TMZ) and lomustine (CCNU) are critical for treating GBM, but resistance mechanisms, including hypomethylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter, undermine treatment. CRISPRoff is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to Glioma Diagnosis and Treatment
Share to RNA regulation and disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39998382
DOI: 10.1093/neuonc/noaf055

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiplexed epigenetic memory editing using CRISPRoff sensitizes glioblastoma to chemotherapyPMID 39998382Read ↗

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastomaSemantic proximity Read ↗

Epigenetic modification and characterization of the <i>MGMT</i> promoter region using CRISPRoff in glioblastoma cellsSemantic proximity Read ↗

Unlocking Glioblastoma Vulnerabilities with CRISPR-Based Genetic ScreeningSemantic proximity Read ↗

In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastomaSemantic proximity Read ↗

Unlocking glioblastoma vulnerabilities with CRISPR-based genetic screeningSemantic proximity Read ↗

In vivo perturb-seq of cancer and microenvironment cells dissects oncologic drivers and radiotherapy responses in glioblastomaSemantic proximity Read ↗

dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant gliomaSemantic proximity Read ↗

Genome scale CRISPR Cas9a knockout screen reveals genes that controls glioblastoma susceptibility to the alkylating agent temozolomideSemantic proximity Read ↗

Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.Semantic proximity Read ↗

Integrated genetic screening reveals FEN1 as a driver of stemness and temozolomide resistance in glioblastomaSemantic proximity Read ↗

AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma.Semantic proximity Read ↗

Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.